Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch.
about
Translating Precision.Reproducibility of PD-L1 assessment in non-small cell lung cancer-know your limits but never stop trying to exceed them.A hindsight reflection on the clinical studies of poly(l-glutamic acid)-paclitaxel.Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.Atezolizumab in advanced non-small cell lung cancer.Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
P2860
Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 25 January 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current Status of Companion an ...... ns for Development and Launch.
@en
Current Status of Companion an ...... ns for Development and Launch.
@nl
type
label
Current Status of Companion an ...... ns for Development and Launch.
@en
Current Status of Companion an ...... ns for Development and Launch.
@nl
prefLabel
Current Status of Companion an ...... ns for Development and Launch.
@en
Current Status of Companion an ...... ns for Development and Launch.
@nl
P2093
P2860
P356
P1476
Current Status of Companion an ...... ns for Development and Launch.
@en
P2093
H Scheerens
J A Williams
P2860
P356
10.1111/CTS.12455
P407
P577
2017-01-25T00:00:00Z